Anavex HISTORISKE OG BANEBRYDENDE RESULTATER I ALZHEIMER!!!
Møder både primære og sekundære endpoints med stor signifikant!!
https://www.anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints
Disse resultater er endda bedre end man turde håbe på.
Prof. Steve Macfarlane:
"People living with Alzheimer's disease desperately need new therapies and I am truly impressed with the outcome of this study, which demonstrated reversal of cognitive decline," said A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. "These results complement and are consistent with findings from the previously completed Alzheimer's disease Phase 2a ANAVEX®2-73 trial, which also demonstrated therapeutic effect on cognition and function. ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer's disease."
Tak for kampen herinde - vi vandt alligevel i sidste ende!
Møder både primære og sekundære endpoints med stor signifikant!!
https://www.anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints
Disse resultater er endda bedre end man turde håbe på.
Prof. Steve Macfarlane:
"People living with Alzheimer's disease desperately need new therapies and I am truly impressed with the outcome of this study, which demonstrated reversal of cognitive decline," said A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. "These results complement and are consistent with findings from the previously completed Alzheimer's disease Phase 2a ANAVEX®2-73 trial, which also demonstrated therapeutic effect on cognition and function. ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer's disease."
Tak for kampen herinde - vi vandt alligevel i sidste ende!
